Form 4: Gilead Sciences CFO Sells 2,500 Shares Under 10b5-1 Trading Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock at $91.35 per share on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, sold 2,500 shares of the company's common stock.
• The sale occurred on January 15, 2025, at a price of $91.35 per share.
• This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 29, 2024.
• Following the transaction, Dickinson directly owns 129,873 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a pre-planned stock sale by an executive, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like Gilead, including peers such as Amgen (AMGN) and Biogen (BIIB).
• These plans allow for scheduled stock sales to avoid any appearance of trading on non-public information.
• The volume of shares sold is relatively small compared to the total outstanding shares of Gilead, and is not unusual for an executive's planned transactions.

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors due to its small size and pre-planned nature.

Key Dates

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, Chief Financial Officer, stock sale, Form 4, 10b5-1 trading plan, insider trading